34 Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): Inclusion criteria Design Treatment Follow-up Main end point - Diabetes (both types) - Hypertension SBP: 160 - 200 mmHg and/or DBP: 95 - 115 mmHg - Left ventricular hypertrophy - Randomized, double blind - Losartan (50 - 100 mg/day) n = 586 - Atenolol (50 - 100 mg/day) n = 609 - 4.7 ± 1.1 years - Combined cardiovascular mortality, stroke, miocardial infarction Lindholm et al., Lancet, 2002
{}